Medical Condition News

RSS

FDA approves brand name VELETRI for Actelion's epoprostenol for injection therapy

Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.

26 Aug 2010

Plantain and broccoli fiber help in Crohn’s disease: Study

New research suggests that plant fibers in plantains and broccoli can help prevent relapses of Crohn's disease. This disease is a long term disease of the gut that is characterized by inflammation of the lining of the digestive system, with symptoms including diarrhea and abdominal pain. Crohn's disease affects between 400,000 and 600,000 people in North America. Scientists believe that rise in processed food and decrease in fibers in diet could be a reason for rise of incidence of this disease.

25 Aug 2010

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m. at The Chemical Heritage Foundation, 315 Chestnut Street, Philadelphia. The event marks the 50th anniversary of the discovery of the first genetic abnormality associated with cancer, and the first to lead to a targeted therapy for cancer.

25 Aug 2010

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc., today announced that the National Institute of Health/National Institute of Allergy and Infectious Disease, has awarded its research partner, the University of Rochester Medical Center (URMC), a $15 million five-year, continuation grant for studies that will utilize ImmuneRegen's Homspera.

25 Aug 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.

25 Aug 2010

New syndicated report highlights medical management of noninfectious uveitis

BioTrends Research Group, Inc. is pleased to announce the publication of a new syndicated report, TreatmentTrends: Noninfectious Uveitis. This report, based on feedback gathered in an on-line survey completed by 72 retinal specialists in June/July 2010, addresses the medical management of noninfectious uveitis (anterior, intermediate, posterior and panuveitis) and referral/co-management patterns between retinal specialists and other specialties.

25 Aug 2010

Mothers show poor mental health even after ending abusive relationship: Study

Even after leaving a violent or controlling relationship, the mental health of mothers may actually get worse before it gets better, a new study suggests. Researchers found that in the two years after the end of an abusive relationship, mothers showed poorer mental health, became more depressed and maintained high levels of anxiety. In those areas, they were no better off than women who stayed in abusive relationships.

25 Aug 2010

Stem cell therapy cures 12-year-old boy with diabetes

Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.

25 Aug 2010

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,781,168 relating to methods of determining heart attack risk by detecting the Ile4399Met genetic polymorphism in the protease-like domain of LPA.

25 Aug 2010

Somaxon Pharmaceuticals, Procter & Gamble to co-promote Silenor

Somaxon Pharmaceuticals, Inc. today announced that Somaxon and Procter & Gamble have entered into a co-promotion agreement for Silenor (doxepin), a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance.

25 Aug 2010

Bioniche, University of Ottawa sign global technology license agreement for botanical therapeutics

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, together with the University of Ottawa, one of Canada's top ten research universities, today announced the signing of an exclusive global license agreement. The agreement provides commercial access for Bioniche to University of Ottawa's technology for botanical therapeutics (natural health) and pharmaceutical compounds for treating anxiety and related conditions in animal health, human health and aquaculture

25 Aug 2010

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein (hsCRP), a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels.

25 Aug 2010

Migraine with aura increases risk of heart disease: Research

Individuals who suffer from migraines with aura (temporary visual or sensory disturbances before or during a migraine headache) are at a higher risk of dying from heart disease or stroke.

25 Aug 2010

Adoption of standby intra-aortic balloon pump strategy during high-risk PCI needed: Study

High-risk patients undergoing a coronary procedure such as placement of a stent who electively received an intra-aortic balloon pump (a device that can help improve blood flow) prior to the procedure did not experience a significantly lower overall rate of events such as heart attack, revascularization or death, according to a study in the August 25 issue of JAMA.

25 Aug 2010

CRT, Bayer Schering Pharma partner to study new leptin antagonist peptides in gynaecological, oncological diseases

Cancer Research Technology has signed an agreement with Bayer Schering Pharma AG, Germany to evaluate new leptin antagonist peptides as potential experimental treatments initially in the area of gynaecological diseases, including cancer.

25 Aug 2010

Vitamin D2 in AbM mushroom can neutralize oxidative stress: Research

Total Nutraceutical Solutions, Inc., announced that it has completed a research study comparing the therapeutic effect of single nutrient forms of synthetic Vitamin D3 and D2 versus natural Vitamin D2 within a whole food. The study focused on the control of Paraquat induced oxidative stress/biologic death.

25 Aug 2010

OXIS International to introduce new ergothioneine-based products for joint health and healthy aging

OXIS INTERNATIONAL, INC. is proud to announce that it will introduce the benefits of Ergothioneine to the consumer market in September 2010 via breakthrough products for joint health and healthy aging. The first products, ErgoFlex® and ErgoPlex®, will initially be marketed via a direct mail offering being developed in partnership with Creative Direct Marketing Group, the leading service provider in the direct mail sector of the direct to consumer channel.

25 Aug 2010

MRI and MR spectroscopy determine internal fat distribution: Study

Why is it that some people lose weight and body fat when they exercise and eat less and others don't. German researchers say MRI and magnetic resonance (MR) spectroscopy can provide the answer and help predict who will benefit from lifestyle changes.

25 Aug 2010

Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting

Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data at this year's Joint International NGM Meeting on Saturday, August 28, 2010.

25 Aug 2010

Physicians decrease LABA/ICS combination therapy for asthma treatment: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that some surveyed physicians indicate that they will decrease their overall prescribing of long-acting beta2 agonists (LABA)/inhaled corticosteroids (ICS) combination therapies over the next 12 months for the treatment of asthma in response to the U.S. Food and Drug Administration's new safety controls for LABA-containing medications.

25 Aug 2010

Medical Condition News

FDA approves brand name VELETRI for Actelion's epoprostenol for injection therapy

Plantain and broccoli fiber help in Crohn’s disease: Study

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

New syndicated report highlights medical management of noninfectious uveitis

Mothers show poor mental health even after ending abusive relationship: Study

Stem cell therapy cures 12-year-old boy with diabetes

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Somaxon Pharmaceuticals, Procter & Gamble to co-promote Silenor

Bioniche, University of Ottawa sign global technology license agreement for botanical therapeutics

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

Migraine with aura increases risk of heart disease: Research

Adoption of standby intra-aortic balloon pump strategy during high-risk PCI needed: Study

CRT, Bayer Schering Pharma partner to study new leptin antagonist peptides in gynaecological, oncological diseases

Vitamin D2 in AbM mushroom can neutralize oxidative stress: Research

OXIS International to introduce new ergothioneine-based products for joint health and healthy aging

MRI and MR spectroscopy determine internal fat distribution: Study

Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting

Physicians decrease LABA/ICS combination therapy for asthma treatment: Survey

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Latest News